Osteomalacia in a hemodialysis patient receiving an active vitamin D sterol
- PMID: 17389892
- DOI: 10.1038/ncpneph0443
Osteomalacia in a hemodialysis patient receiving an active vitamin D sterol
Abstract
Background: A 17-year-old Filipino male hemodialysis patient presented for renal transplant evaluation. He had significant skeletal abnormalities characterized by bone pain, an inability to walk, and secondary hyperparathyroidism despite therapy with an active vitamin D sterol (paricalcitol).
Investigations: The patient underwent a physical examination, and his serum levels of calcium, phosphorus, alkaline phosphatase, parathyroid hormone, aluminum and 25-hydroxycholecalciferol (25OH-vitamin D) were determined. X-rays of hips and lower extremities, MRI, and bone histomorphometry after double tetracycline labeling were performed.
Diagnosis: Osteomalacia associated with low 25OH-vitamin D levels.
Management: Monthly therapy with ergocalciferol (vitamin D2) and discontinuation of paricalcitol.
Similar articles
-
Intravenous paricalcitol for treatment of secondary hyperparathyroidism in children on hemodialysis.Am J Kidney Dis. 2007 Jun;49(6):814-23. doi: 10.1053/j.ajkd.2007.03.008. Am J Kidney Dis. 2007. PMID: 17533024 Clinical Trial.
-
1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.Dan Med Bull. 2008 Nov;55(4):186-210. Dan Med Bull. 2008. PMID: 19232159 Review.
-
Emerging role for the vitamin D receptor activator (VDRA), paricalcitol, in the treatment of secondary hyperparathyroidism.Expert Opin Pharmacother. 2008 Apr;9(6):947-54. doi: 10.1517/14656566.9.6.947. Expert Opin Pharmacother. 2008. PMID: 18377338 Review.
-
Beneficial effects of better control of secondary hyperparathyroidism with paricalcitol in chronic dialysis patients.J Nephrol. 2009 Jan-Feb;22(1):59-68. J Nephrol. 2009. PMID: 19229819
-
Oral paricalcitol for the treatment of secondary hyperparathyroidism in patients on hemodialysis or peritoneal dialysis.Am J Nephrol. 2008;28(1):97-106. doi: 10.1159/000109398. Epub 2007 Oct 3. Am J Nephrol. 2008. PMID: 17914251 Clinical Trial.
Cited by
-
Osteoporosis, bone mineral density and CKD-MBD: treatment considerations.J Nephrol. 2017 Oct;30(5):677-687. doi: 10.1007/s40620-017-0404-z. Epub 2017 Apr 21. J Nephrol. 2017. PMID: 28432640 Review.
-
Case report: Osteomalacia due to bisphosphonate treatment in a patient on hemodialysis.BMC Nephrol. 2021 Sep 3;22(1):298. doi: 10.1186/s12882-021-02509-5. BMC Nephrol. 2021. PMID: 34479496 Free PMC article.
-
Vitamin D3 Release from MgO Doped 3D Printed TCP Scaffolds for Bone Regeneration.ACS Biomater Sci Eng. 2024 Mar 11;10(3):1676-1685. doi: 10.1021/acsbiomaterials.3c01779. Epub 2024 Feb 22. ACS Biomater Sci Eng. 2024. PMID: 38386843 Free PMC article.
-
Mineral metabolism and bone abnormalities in children with chronic renal failure.Rev Endocr Metab Disord. 2008 Jun;9(2):131-7. doi: 10.1007/s11154-007-9071-z. Epub 2008 Jan 4. Rev Endocr Metab Disord. 2008. PMID: 18175221 Review.
-
Osteomalacia induced by vitamin D deficiency in hemodialysis patients: the crucial role of vitamin D correction.J Bone Miner Metab. 2014 Mar;32(2):215-9. doi: 10.1007/s00774-013-0480-7. Epub 2013 Jun 21. J Bone Miner Metab. 2014. PMID: 23794122
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical